Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.44 |
| ▸ | PFKFB3 | Q16875 | 4/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | GLP1R | P43220 | 1/20 | 0.40 |
| ▸ | CD38 | P28907 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3212547 | 1.00 | LMNA (0.45) | LMNAHDAC6KCNN3PFKFB3ADRA2A | |
| SCHEMBL1551824 | 1.00 | LMNA (0.45) | LMNAHDAC6KCNN3PFKFB3ADRA2A | |
| SCHEMBL1552285 | 0.93 | PDPK1 (0.43) | ADRA2BADRA2CADRA1A | |
| SCHEMBL1551689 | 0.93 | PDPK1 (0.43) | ADRA2BADRA2CADRA1A | |
| SCHEMBL5434980 | 0.86 | PFKFB3 (0.39) | LMNAHDAC6PFKFB3DHFRCD38 | |
| SCHEMBL1551293 | 0.86 | PFKFB3 (0.39) | LMNAHDAC6PFKFB3DHFRCD38 | |
| SCHEMBL5428899 | 0.86 | PFKFB3 (0.39) | LMNAHDAC6PFKFB3DHFRCD38 | |
| SCHEMBL21524773 | 0.82 | PFKFB3 (0.52) | LMNAHDAC6KCNN3PFKFB3ADRA2A | |
| SCHEMBL1552304 | 0.82 | TAS1R3 (0.39) | LMNADHFR | |
| SCHEMBL1551773 | 0.82 | TAS1R3 (0.39) | LMNADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2012588-B1 | AQUEOUS SUSPENSION CONCENTRATE | BAYER CROPSCIENCE AG (DE) | 2011-04-27 | — | — | EP | disclosed |
| US-20100048400-A1 | HERBICIDE COMBINATION | BAYER CROPSCIENCE AG (DE) | 2010-02-25 | — | — | US | disclosed |
| EP-2147600-A1 | Method for weed control in lawn | Bayer CropScience AG (DE) | 2010-01-27 | — | — | EP | disclosed |
| EP-1958509-A1 | Herbicide combination | Bayer CropScience AG (DE) | 2008-08-20 | — | — | EP | disclosed |
| EP-1854355-A1 | Aqueous suspension concentrates | Bayer CropScience AG (DE) | 2007-11-14 | — | — | EP | disclosed |
| US-20070219095-A1 | AQUEOUS SUSPENSION CONCENTRATES | BAYER CROPSCIENCE GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-20070123424-A1 | AQUEOUS SUSPENSION CONCENTRATES | BAYER CROPSCIENCE GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1790227-A1 | Aqueous suspension-concentrates of 2,4-diamino-s-triazine herbicides | Bayer CropScience AG (DE) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123424-A1 | AQUEOUS SUSPENSION CONCENTRATES | ASH2L, SPATS2L, AS3MT | LMNA 4624/4885HDAC6 2426/4885KCNN3 2331/4885 |
| US-20070219095-A1 | AQUEOUS SUSPENSION CONCENTRATES | SLC43A1, AS3MT, SLC7A5 | LMNA 4673/4885HDAC6 3446/4885KCNN3 1335/4885 |
| US-20100048400-A1 | HERBICIDE COMBINATION | DDT, DRD1, DRD2 | LMNA 4777/4885HDAC6 2212/4885KCNN3 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.